Items Per Page 102550 Year All20242023202220212020201920182017 October 13, 2023 ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress PDF Version September 22, 2023 ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress PDF Version September 7, 2023 ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference PDF Version August 11, 2023 ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update PDF Version July 6, 2023 ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis PDF Version June 23, 2023 ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis PDF Version June 22, 2023 ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan PDF Version June 1, 2023 ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference PDF Version May 18, 2023 ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata PDF Version May 15, 2023 ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting PDF Version
October 13, 2023 ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress PDF Version
September 22, 2023 ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress PDF Version
September 7, 2023 ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference PDF Version
August 11, 2023 ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update PDF Version
July 6, 2023 ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis PDF Version
June 23, 2023 ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis PDF Version
June 22, 2023 ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan PDF Version
June 1, 2023 ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference PDF Version
May 18, 2023 ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata PDF Version
May 15, 2023 ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting PDF Version